<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802255</url>
  </required_header>
  <id_info>
    <org_study_id>ECSEVO-LT-011</org_study_id>
    <secondary_id>2011-002555-34</secondary_id>
    <nct_id>NCT01802255</nct_id>
  </id_info>
  <brief_title>Sevoflurane- Safety in Long-term Sedation Procedures</brief_title>
  <official_title>Study of the Safety of Administration of Sevoflurane for Long-term Critically Ill Patients Sedation Undergoing Mechanical Ventilation. Prospective, Controlled, Randomized, Multicenter, Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>F Javier Belda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients needing intensive care often require sedative drugs to reduce anxiety and agitation&#xD;
      during ventilator care and invasive therapeutic and diagnostic procedures. At present there&#xD;
      is no optimal sedative agent for these patients. The most commonly used sedative agents in&#xD;
      intensive care units are midazolam and propofol. Both drugs have side effects of clinical&#xD;
      importance.&#xD;
&#xD;
      At present, a viable alternative to intravenous sedation is inhalatory sedation. Sevoflurane,&#xD;
      as other inhaled anesthetic agents, is sedative in low doses. A new simplified method of&#xD;
      administration of isoflurane or sevoflurane has been developed. The Anesthetic Conserving&#xD;
      Device is a modified heat-moisture exchanger (HME) that permits direct infusion of&#xD;
      sevoflurane to the airway, where it is vaporized in an evaporator rod in the device.&#xD;
&#xD;
      However, the use of sevoflurane is limited to anesthesia and sedation lasting no more than 12&#xD;
      hours, since the possible renal problems posed by inorganic fluoride in prolonged operations&#xD;
      remain the subject of controversy.&#xD;
&#xD;
      The primary aim (and primary hypothesis) of the current trial is to determine whether&#xD;
      sevoflurane can be administered as a sedative drug for more than 48 hours without clinically&#xD;
      relevant physiopathological effects on kidney and liver function.&#xD;
&#xD;
      Other end-points of the trial are to evaluate the quality of sedation of sevoflurane, in&#xD;
      terms of sedation control, the rapidity and predictability of awakening, and the incidence of&#xD;
      delirium in critical care patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of recruitment in the Centres&#xD;
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maintenance of renal function.</measure>
    <time_frame>Baseline. Posteriorly, every 12 hours for the full length of sedation. After sedation, every 24 hours up to one week</time_frame>
    <description>Measurements in plasma: creatinine and cystatin levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of liver function</measure>
    <time_frame>Baseline. Posteriorly, every 12 hours for the full length of sedation. After sedation, every 24 hours up to one week</time_frame>
    <description>Measurements in plasma: SGOT (aspartate aminotransferase, AST), SGPT (alanine aminotransferase, ALT), LDH (lactate dehydrogenase) alkaline phosphatase, conjugated and total bilirubin, cholesterol, triglycerides, albumin, total proteins, electrolytes and glycogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics of fluoride</measure>
    <time_frame>Baseline. Posteriorly, every 12 hours for the full length of sedation. After sedation, every 24 hours up to one week</time_frame>
    <description>Determine evolutionary plasmatic levels of fluorides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of delirium</measure>
    <time_frame>Baseline. Posteriorly, every 12 hours for the full length of sedation. After sedation, every 24 hours up to one week</time_frame>
    <description>The incidence of delirium will be evaluated by the CAM-ICU method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Poisoning by Inhaled Anaesthetic</condition>
  <condition>Fluoride Poisoning</condition>
  <condition>Recovery From Sedation</condition>
  <condition>Renal Function</condition>
  <condition>Hepatic Function</condition>
  <arm_group>
    <arm_group_label>Inhalatory sedation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevoflurane given via AnaConDa for sedation minimum 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam given intravenously for sedation minimum 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sedation with inhaled anesthetic via AnaConDa.</description>
    <arm_group_label>Inhalatory sedation</arm_group_label>
    <other_name>Sevorane, Ultane, Sojourn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Intravenous sedation.</description>
    <arm_group_label>Intravenous sedation</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signing of the informed consent document (patient or relatives).&#xD;
&#xD;
          -  Patient age 18 years or older.&#xD;
&#xD;
          -  Expected minimum duration of sedation: 48 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic renal failure treated with replacement therapy (hemodialysis or peritoneal&#xD;
             dialysis).&#xD;
&#xD;
          -  Acute kidney injury in Stage 3 of AKIN classification&#xD;
&#xD;
          -  Grade C hepatic Child-Pugh classification&#xD;
&#xD;
          -  Established Acute Respiratory Distress Syndrome (ARDS).&#xD;
&#xD;
          -  Central nervous system pathology with cognitive disorders that not allow performing&#xD;
             the test of the study: severe dementia, Alzheimer's disease, depression,&#xD;
             schizophrenia, acute stroke.&#xD;
&#xD;
          -  Head trauma with Glasgow &lt;12.&#xD;
&#xD;
          -  Patient treated with antiepileptic drugs that must be maintained during the study&#xD;
             period&#xD;
&#xD;
          -  Patients requiring the use of neuromuscular blocking agents during the infusion of&#xD;
             study drug, except for the insertion of the endotracheal tube.&#xD;
&#xD;
          -  Epidural or spinal analgesia&#xD;
&#xD;
          -  Allergy or known hypersensitivity to any of the study drugs&#xD;
&#xD;
          -  Patients with known or suspected genetic susceptibility to malignant hyperthermia&#xD;
&#xD;
          -  Previous participation in this trial&#xD;
&#xD;
          -  Participation in another clinical trial within 4 weeks prior to selection.&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Soro, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínico Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luciano Aguilera, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Basurto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Soria, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Asistencial de León</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Acosta, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Kong KL, Bion JF. Sedating patients undergoing mechanical ventilation in the intensive care unit--winds of change? Br J Anaesth. 2003 Mar;90(3):267-9.</citation>
    <PMID>12594134</PMID>
  </reference>
  <reference>
    <citation>Röhm KD, Wolf MW, Schöllhorn T, Schellhaass A, Boldt J, Piper SN. Short-term sevoflurane sedation using the Anaesthetic Conserving Device after cardiothoracic surgery. Intensive Care Med. 2008 Sep;34(9):1683-9. doi: 10.1007/s00134-008-1157-x. Epub 2008 May 24.</citation>
    <PMID>18500419</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 9, 2013</study_first_submitted>
  <study_first_submitted_qc>February 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</investigator_affiliation>
    <investigator_full_name>F Javier Belda</investigator_full_name>
    <investigator_title>Prof. Dr. F Javier Belda</investigator_title>
  </responsible_party>
  <keyword>Inhalatory sedation</keyword>
  <keyword>Sevoflurane</keyword>
  <keyword>AnaConDa</keyword>
  <keyword>Nephrotoxicity</keyword>
  <keyword>Hepatotoxicity</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Propofol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poisoning</mesh_term>
    <mesh_term>Fluoride Poisoning</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shared data will be anonymous</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

